Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Hold" Rating from Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)'s stock had its "hold" rating restated by analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports.

Several other research analysts also recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Wednesday. Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the stock an "outperform" rating in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $5.00.

Lexicon Pharmaceuticals Trading Down 7.7 %

Shares of NASDAQ:LXRX traded down $0.06 during trading hours on Wednesday, hitting $0.76. 4,049,932 shares of the company's stock traded hands, compared to its average volume of 5,387,939. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The business has a fifty day moving average price of $0.78 and a 200-day moving average price of $1.36. Lexicon Pharmaceuticals has a 1 year low of $0.62 and a 1 year high of $3.73. The firm has a market capitalization of $186.21 million, a P/E ratio of -1.01 and a beta of 1.06.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $1.75 million for the quarter, compared to analysts' expectations of $3.14 million. During the same quarter in the previous year, the firm earned ($0.21) EPS. Equities analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in LXRX. Dimensional Fund Advisors LP raised its holdings in shares of Lexicon Pharmaceuticals by 52.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 76,086 shares of the biopharmaceutical company's stock valued at $128,000 after purchasing an additional 26,143 shares in the last quarter. Marshall Wace LLP raised its stake in Lexicon Pharmaceuticals by 138.5% in the second quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company's stock worth $2,000,000 after buying an additional 691,276 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Lexicon Pharmaceuticals by 40.5% during the second quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company's stock worth $84,000 after buying an additional 14,411 shares during the period. Point72 Asset Management L.P. boosted its position in Lexicon Pharmaceuticals by 605.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company's stock valued at $6,924,000 after acquiring an additional 3,536,805 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Lexicon Pharmaceuticals by 107.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 23,893 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.